

Clinical Policy: Fractional Exhaled Nitric Oxide

Reference Number: CP.MP.103

Last Review Date: 11/19

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Fractional exhaled nitric oxide (FeNO) measurement is a noninvasive and simple test thought to reflect eosinophilic airway inflammation. While measurement of FeNO is standardized, there are currently no reference guidelines available to aid practitioners in appropriately applying test results in practice.

Policy/Criteria

It is the policy of health plans affiliated with Centene Corporation[®] that testing for fractionated exhaled nitric oxide (FeNO) is **investigational** for diagnosing and guiding the treatment of asthma, as well as all other conditions, as there is insufficient evidence proving it more than or as effective as existing standards of care.

Background

There are multiple methods for diagnosing and assessing control of asthma and, according to the American Thoracic Society (ATS), no single test is an adequate indicator of asthma control.¹ Conventional, objective methods to assess asthma include spirometry/peak flow and degree of airway hyper-responsiveness.² These methods are often used as measures of asthma control in addition to patient symptoms, clinical questionnaires, and use of rescue medications.^{2,3} Newer methods of diagnosing and assessing control of asthma include the use of biomarkers of airway inflammation such as FeNO and induced sputum analysis.⁴

FeNO describes the levels of exhaled nitric oxide (NO) in the breath and NO is a mediator involved in lung inflammation that is largely formed in the lower airways.⁵ Increased levels of FeNO are associated with eosinophilic inflammation, severe asthma, and inhaled glucocorticoid-naïve asthma.⁴ Although there are some correlations between FeNO and characteristics related to asthma, there is large variability in FeNO levels between individuals. Other factors that may affect FeNO include atopy, sex, age, and cigarette smoking.³ However, there are no established guidelines for adjusting FeNO values according to these factors,³ potentially making the test less accurate for certain populations.

There are currently three types of FeNO tests approved by the FDA⁵ and there is a large body of literature on FeNO testing for the diagnosis and management of asthma. Overall, the evidence is mixed for using FeNO as an adjunct to the diagnosis or management of asthma. Multiple studies have shown that FeNO can serve as an indicator of glucocorticoid response.^{3,4,6} However, large studies, randomized control trials and a meta-review have found no clinical benefit to the use of FeNO testing over other methods of assessing or managing asthma.^{2,4,7-9}

Among the studies that found a benefit to the use of FeNO testing,^{6,10-13} there was little agreement regarding FeNO cutoff values which would indicate asthma diagnosis or control.^{3,5} Although the ATS has recommended specific FeNO cutoff values to serve as guidelines for the

CLINICAL POLICY
Fractional Exhaled Nitric Oxide

diagnosis and treatment of asthma,¹⁴ these standardized values have not been consistently used in the research to date on FeNO testing.³⁻⁵ An additional drawback to FeNO testing for the diagnosis or management of asthma is that it is most indicative of inflammation caused by eosinophils, which characterizes only one subtype of asthma.⁴

A 2016 Cochrane Review evaluating the use of FeNO in guiding treatment for adults with asthma concluded that, while management guided by FeNO levels results in reduced exacerbations, it cannot be advocated universally since it does not affect day-to-day clinical symptoms, end-of-study FeNO levels, or inhaled corticosteroid dose.¹⁵ Furthermore, a systematic review and meta-analysis evaluating the diagnostic accuracy of FeNO in asthmatic children found that FeNO has only moderate diagnostic performance.¹⁶

Given the equivocal results of research on the accuracy and usefulness of FeNO testing for the diagnosis and management of asthma, the lack of standardized cutoff values, and the need for further study, FeNO testing for the diagnosis and/or management of asthma is considered experimental, investigational, or unproven.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
95012	Nitric Oxide expired gas determination

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
N/A	

Reviews, Revisions, and Approvals	Date	Approval Date
Policy created	12/15	01/16
Changed FeNO to investigational from not medically necessary. References reviewed and updated, along with background information.	12/16	01/17
References reviewed and updated.	12/17	01/18
References reviewed and updated.	12/18	12/18
References reviewed and updated.	11/19	11/19

Reviews, Revisions, and Approvals	Date	Approval Date
Added that testing FeNO is investigational for all other conditions, in addition to asthma, with supporting sources.	12/19	12/19

References

1. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations; standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med.* 2009; 180: 602-615. doi: 10.1164/rccm.200801-060ST
2. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax.* 2012; 67: 199-208. doi:10.1136/thx.2010.135574
3. Dweik RA. Exhaled nitric oxide analysis and applications. UpToDate. Barnes PJ (Ed.). Accessed December 6, 2019.
4. Wadsworth SJ, Sin DD, Dorscheid DR. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. *J Asthma Allergy.* 2011; 4: 77-86. <http://dx.doi.org/10.2147/JAA.S15081>
5. Hayes Medical Technology Directory: Nitric oxide breath analysis for the diagnosis of asthma. Hayes. Published October 6, 2016. Annual Review October 8, 2018.
6. Hayes Medical Technology Directory: Nitric oxide breath analysis for the management of asthma. Hayes. Published September 29, 2016. Annual Review October 8, 2018.
7. Donohue JF, Jain N. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. *Respiratory Med.* 2013; 107: 943-952.
8. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. *JAMA.* 2012; 10; 987-997. doi: 10.1001/2012.jama.10893
9. Szeffler SJ, Mitchell H, Sorkness CA, et al. Adding exhaled nitric oxide to guideline-based asthma treatment in inner-city adolescents and young adults: a randomized controlled trial. *Lancet.* 2008; 372(9643): 1065-1072. doi: 10.1016/S0140-6736(08)61448-8
10. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management. *Am J Respir Crit Care Med.* 2007; 176(3): 231-237. doi: 10.1164/rccm.200610-1427OC
11. Sippel JM, Holden WE, Tilles SA, et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. *J Allergy Clin Immunol.* 2000; 106: 645-50. doi:10.1067/mai.2000.109618
12. Dupont LJ, Demedts MG, Verleden M. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. *Chest.* 2003; 123(3): 751-756. doi:10.1378/chest.123.3.751
13. Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma comparisons between exhaled nitric oxide measurements and conventional tests. *Am J Respir Crit Care Med.* 2004; 169: 473-478. doi: 10.1164/rccm.200310-1376OC
14. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *Lancet.* 2011; 378(9795): 983-990. [http://dx.doi.org/10.1016/S0140-6736\(11\)60971-9](http://dx.doi.org/10.1016/S0140-6736(11)60971-9).

CLINICAL POLICY

Fractional Exhaled Nitric Oxide

15. Dweik RA, Boggs RB, Erzurum SC, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. *Am J Respir Crit Care Med*. 2011; 184: 602-615. doi: 10.1164/rccm.912011ST
16. Petsky HL, Kew KM, Turner C, Change AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. *Cochrane Database Syst Rev*. 2016 Sep 1;9: CD011440.
17. Tang S, Xie Y, Yuan C, Sun X, Cui Y. Fractional exhaled nitric oxide for diagnosis of childhood asthma: a systematic review and meta-analysis. *Clin Rev Allergy Immunol*. 2016 Jul 21.
18. Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Asthma Management and Prevention.
19. Global Initiative for Chronic Obstructive Lung Disease. 2019 Report, Pocket guide to COPD diagnosis, management and prevention: a guide for health care professionals.
20. Qaseem A, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med*. 2011 Aug 2;155(3):179-91.
21. Horváth I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. *Eur Respir J*. 2017;49(4).
22. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. *Chest*. 2010 Sep;138(3):682-92.

Important reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

CLINICAL POLICY

Fractional Exhaled Nitric Oxide

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.